| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Oncology, Markers, Clinical Correlates |
Pathology Unit of the "F.Addarii" Institute of Oncology, Department of Hematology-Oncology, University of Bologna, 40138 Bologna, Italy [M. F., A. A., A. D., B. C., C. B., W. F. G.], Department of Pathology, Brigham and Women’s Hospital and Adult Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115 [M. L.]
The p27 cyclin-dependent kinase inhibitor is a negative regulator of cell-cycle progression. In many human epithelial malignancies, decreased expression of p27 correlates with high grade, early recurrence, and poor prognosis. To evaluate the prognostic significance of p27 in hepatocellular carcinoma (HCC), we studied 54 HCCs along with corresponding nontumoral tissue. Immunohistochemistry (IHC) and Western blot (WB) analysis before and after immunoprecipitation with Cdk2 were performed on paraffinembedded tissues and protein homogenates, respectively, to compare localization and expression of the p27 protein and to determine the total and active (Cdk2-bound) fractions of p27. Correlations were analyzed between IHC-assessed levels of p27, survival, and major clinical and pathological variables. IHC revealed no p27 expression in the majority of hepatocytes from normal and cirrhotic liver, whereas 14 HCCs (26%) were high p27 expressers (>50% positive cells), 26 (48%) low expressers (<50% positive cells), and 14 (26%) negative. High IHC signals of p27 correlated with Cdk2-bound p27 as assessed by immunoprecipitation-WB; by contrast, WB alone displayed similar levels of p27 protein in all normal and tumoral samples. High IHC p27 expression correlated with prolonged survival (P = 0.027), whereas the presence of cirrhosis was associated with poor outcome (P = 0.029). We conclude that with respect to their nonneoplastic counterparts, a subset of HCCs acquire significant p27 expression and that high expression of p27 is a favorable independent prognostic parameter for HCC.
This article has been cited by other articles:
|
|
 |
|
  Y. Yuan, J. Wang, J. Li, L. Wang, M. Li, Z. Yang, C. Zhang, and J. L. Dai Frequent Epigenetic Inactivation of Spleen Tyrosine Kinase Gene in Human Hepatocellular Carcinoma. Clin. Cancer Res., November 15, 2006; 12(22): 6687 - 6695. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Varghese, C. Agarwal, A. Tyagi, R. P. Singh, and R. Agarwal Silibinin Efficacy against Human Hepatocellular Carcinoma Clin. Cancer Res., December 1, 2005; 11(23): 8441 - 8448. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. B. Thomas and J. L. Abbruzzese Opportunities for Targeted Therapies in Hepatocellular Carcinoma J. Clin. Oncol., November 1, 2005; 23(31): 8093 - 8108. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Carloni, F. Vizzutti, and P. Pantaleo Farnesyltransferase Inhibitor, ABT-100, Is a Potent Liver Cancer Chemopreventive Agent Clin. Cancer Res., June 1, 2005; 11(11): 4266 - 4274. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. P. Claudio, G. Russo, C. A. C. Y. Kumar, C. Minimo, A. Farina, S. Tutton, G. Nuzzo, F. Giuliante, G. Angeloni, V. Maria, et al. pRb2/p130, Vascular Endothelial Growth Factor, p27(KIP1), and Proliferating Cell Nuclear Antigen Expression in Hepatocellular Carcinoma: Their Clinical Significance Clin. Cancer Res., May 15, 2004; 10(10): 3509 - 3517. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Denicourt and S. F. Dowdy Cip/Kip proteins: more than just CDKs inhibitors Genes & Dev., April 15, 2004; 18(8): 851 - 855. [Full Text] [PDF]
|
|
|
|
|
|
C. Armengol, G. Tarafa, L. Boix, M. Sole, R. Queralt, D. Costa, O. Bachs, J. Bruix, and G. Capella Orthotopic Implantation of Human Hepatocellular Carcinoma in Mice: Analysis of Tumor Progression and Establishment of the BCLC-9 Cell Line Clin. Cancer Res., March 15, 2004; 10(6): 2150 - 2157. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Fiorentino, A. Altimari, M. Ravaioli, E. Gruppioni, E. Gabusi, B. Corti, M. Vivarelli, P.-P. Bringuier, J.-Y. Scoazec, W. F. Grigioni, et al. Predictive Value of Biological Markers for Hepatocellular Carcinoma Patients Treated with Orthotopic Liver Transplantation Clin. Cancer Res., March 1, 2004; 10(5): 1789 - 1795. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Matsuda, T. Ichida, T. Genda, S. Yamagiwa, Y. Aoyagi, and H. Asakura Loss of p16 Contributes to p27 Sequestration by Cyclin D1-Cyclin-dependent Kinase 4 Complexes and Poor Prognosis in Hepatocellular Carcinoma Clin. Cancer Res., August 1, 2003; 9(9): 3389 - 3396. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Fiorentino, A. Altimari, A. D'Errico, E. Gabusi, P. Chieco, M. Masetti, and W. F. Grigioni Low p27 Expression Is an Independent Predictor of Survival for Patients with Either Hilar or Peripheral Intrahepatic Cholangiocarcinoma Clin. Cancer Res., December 1, 2001; 7(12): 3994 - 3999. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. GOUKASSIAN, A. DIEZ-JUAN, T. ASAHARA, P. SCHRATZBERGER, M. SILVER, T. MURAYAMA, J. M. ISNER, and V. ANDRES Overexpression of p27Kip1 by doxycycline-regulated adenoviral vectors inhibits endothelial cell proliferation and migration and impairs angiogenesis FASEB J, September 1, 2001; 15(11): 1877 - 1885. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |
